Latest news with #AnalystandInvestorDay
Associated Press
03-06-2025
- Business
- Associated Press
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Jun 3, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. 'We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achievements have positioned us to take the next bold step in our journey of growth and transformation. We are excited to share our vision for the future—one that builds on our successes, leverages our capabilities, and propels us toward making an even greater impact delivering meaningful solutions for patients,' said John Shannon, Chief Executive Officer. Path to Long Term Value Creation Financial Guidance & Long-range Outlook 2025 Analyst and Investor Day Event Details The Company's first in-person and virtual analyst and investor day will be in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EDT. To access the live webcast of the event, please use this link: A replay of the webcast, along with the related presentation materials, will be available on the 'Events & Presentations' section of the Company's Investor Relations website following the conclusion of the event. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used during radiology exams as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including statements regarding financial guidance for 2025, including its expected total revenue and commitment to remaining adjusted EBITDA positive, the outlook for 2030 and outlook for 2035 and beyond, including statements regarding total revenue, product growth, annual net revenue expected for Recorlev® and XP-8121, the market and therapeutic potential of its products and product candidates, including Recorlev and XP-8121, the ability to continue to demonstrate rapid revenue growth, sustained momentum across the portfolio and maintain disciplined execution of the Company's growth strategy, the beneficial impact on the lives of patients, including XP-8121's potential to transform the treatment landscape for millions living with hypothyroidism, capital management enabling the self-funding of both near and long-term growth, and other statements containing the words 'will,' 'would,' 'continue,' 'expect,' 'should,' 'anticipate,' 'new,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris' experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris' actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its collaborators' ability to protect its intellectual property and proprietary technology, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs, and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris' filings, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. View source version on CONTACT: Xeris Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications [email protected] KEYWORD: ILLINOIS NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: OTHER HEALTH RESEARCH MANAGED CARE GENERAL HEALTH PHARMACEUTICAL MEDICAL DEVICES CLINICAL TRIALS SCIENCE BIOTECHNOLOGY MEDICAL SUPPLIES OTHER SCIENCE HEALTH SOURCE: Xeris Biopharma Holdings, Inc. Copyright Business Wire 2025. PUB: 06/03/2025 07:30 AM/DISC: 06/03/2025 07:31 AM
Business Wire
03-06-2025
- Business
- Business Wire
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. 'We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achievements have positioned us to take the next bold step in our journey of growth and transformation. We are excited to share our vision for the future—one that builds on our successes, leverages our capabilities, and propels us toward making an even greater impact delivering meaningful solutions for patients," said John Shannon, Chief Executive Officer. Path to Long Term Value Creation Proven track record of strong execution — successfully developed and launched a portfolio of products that address unmet medical needs. Recorlev® revenue acceleration has propelled Xeris to a pivotal inflection point, marking a new phase of expected growth. Financial strength enables self-funding of near- and long-term growth — driven by rapid revenue growth and disciplined capital management. XP-8121 has the potential to transform the treatment landscape for millions living with hypothyroidism, reinforcing the Company's commitment to innovation. Financial Guidance & Long-range Outlook 2025 Guidance: The Company reaffirms total revenue in the range of $260 to $275 million and its commitment to remaining adjusted EBITDA positive going forward. 2030 Outlook: The Company expects total revenue of approximately $750 million, reflecting growth across our current portfolio of products, with Recorlev® leading the way. 2035 Outlook & Beyond: The Company anticipates Recorlev® annual net revenue of approximately $1 billion in 2035. XP-8121 peak net revenue is expected to be $1 to $3 billion. 2025 Analyst and Investor Day Event Details The Company's first in-person and virtual analyst and investor day will be in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EDT. To access the live webcast of the event, please use this link: A replay of the webcast, along with the related presentation materials, will be available on the "Events & Presentations" section of the Company's Investor Relations website following the conclusion of the event. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used during radiology exams as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including statements regarding financial guidance for 2025, including its expected total revenue and commitment to remaining adjusted EBITDA positive, the outlook for 2030 and outlook for 2035 and beyond, including statements regarding total revenue, product growth, annual net revenue expected for Recorlev® and XP-8121, the market and therapeutic potential of its products and product candidates, including Recorlev and XP-8121, the ability to continue to demonstrate rapid revenue growth, sustained momentum across the portfolio and maintain disciplined execution of the Company's growth strategy, the beneficial impact on the lives of patients, including XP-8121's potential to transform the treatment landscape for millions living with hypothyroidism, capital management enabling the self-funding of both near and long-term growth, and other statements containing the words 'will,' 'would,' 'continue,' 'expect,' 'should,' 'anticipate,' 'new,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris' experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris' actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its collaborators' ability to protect its intellectual property and proprietary technology, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs, and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris' filings, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.
Yahoo
30-05-2025
- Business
- Yahoo
Raymond James Lifts Coherent Corp. (COHR)'s Stock Price Target to $96, Maintains Strong Buy Rating
Raymond James analyst Simon Leopold on Wednesday raised Coherent Corp. (NYSE:COHR)'s stock price target to $96 from $91, while maintaining the Strong Buy rating for its shares. The revision followed Coherent Corp. (NYSE:COHR)'s Analyst and Investor Day earlier in the day, in which the company shared its long-term growth targets that surpassed both Raymond James' and the broader market's expectations. A row of precision industrial lasers in action, cutting the most intricate of shapes. Coherent Corp. (NYSE:COHR)'s management outlined its goals, such as aiming for a gross margin greater than 42% and an operating margin above 24%, indicating that by 2028, the company could achieve an EPS of around $8-9, which will be a substantial increase from forecasts of under $4 in fiscal 2025. Considering these ambitious targets, Raymond James lifted the stock's target price to account for the anticipated gross margin expansion and growth in the industrial laser sector. Moreover, on May 7, Coherent Corp. (NYSE: COHR) reported impressive results for the third quarter of fiscal 2025, with revenue increasing 24% year-over-year to $1.5 billion, driven by strong demand for AI-related data centers. Earnings per share were posted at $0.91, beating estimates by five cents. While we acknowledge the potential of COHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than COHR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: ChatGPT Stock Advice: Top 12 Stock Recommendations and 10 Cheap Rising Stocks to Buy Right Now. Disclosure: None.
Yahoo
29-05-2025
- Business
- Yahoo
Raymond James Lifts Coherent Corp. (COHR)'s Stock Price Target to $96, Maintains Strong Buy Rating
Raymond James analyst Simon Leopold on Wednesday raised Coherent Corp. (NYSE:COHR)'s stock price target to $96 from $91, while maintaining the Strong Buy rating for its shares. The revision followed Coherent Corp. (NYSE:COHR)'s Analyst and Investor Day earlier in the day, in which the company shared its long-term growth targets that surpassed both Raymond James' and the broader market's expectations. A row of precision industrial lasers in action, cutting the most intricate of shapes. Coherent Corp. (NYSE:COHR)'s management outlined its goals, such as aiming for a gross margin greater than 42% and an operating margin above 24%, indicating that by 2028, the company could achieve an EPS of around $8-9, which will be a substantial increase from forecasts of under $4 in fiscal 2025. Considering these ambitious targets, Raymond James lifted the stock's target price to account for the anticipated gross margin expansion and growth in the industrial laser sector. Moreover, on May 7, Coherent Corp. (NYSE: COHR) reported impressive results for the third quarter of fiscal 2025, with revenue increasing 24% year-over-year to $1.5 billion, driven by strong demand for AI-related data centers. Earnings per share were posted at $0.91, beating estimates by five cents. While we acknowledge the potential of COHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than COHR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: ChatGPT Stock Advice: Top 12 Stock Recommendations and 10 Cheap Rising Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28-05-2025
- Business
- Business Wire
Xponential Fitness, Inc. to Host Analyst and Investor Day Tomorrow
IRVINE, Calif.--(BUSINESS WIRE)--Xponential Fitness, Inc. (NYSE: XPOF) (the 'Company' or 'Xponential'), one of the leading global franchisors of boutique health and wellness brands, will host an Analyst and Investor Day tomorrow, Thursday, May 29, 2025, to be held at the New York Stock Exchange (NYSE) in New York, NY, beginning at approximately 9:00 a.m. ET. The event will feature presentations by members of the Xponential management team, including Mark King, CEO, John Meloun, CFO, John Kawaja, President, North America, and Tim Weiderhoft, COO, and will focus on the Company's operations, strategy and commitment to stockholder value. A question and answer session (Q&A) will follow. A live webcast of the Analyst and Investor Day will be available on the Investor Relations section of Xponential's website at For those unable to join for the live presentations, a replay of the webcast will be available through the Investor Relations section of the Company's website following the event. Following the conclusion of the Analyst and Investor Day, Xponential management will ring The Closing Bell ® at the New York Stock Exchange. A live webcast of the ceremony will be available beginning at 3:59 p.m. ET at the NYSE's website For additional details on the event, please reach out to investor@ About Xponential Fitness, Inc. Xponential Fitness, Inc. (NYSE: XPOF) is one of the leading global franchisors of boutique health and wellness brands. Through its mission to deliver the talents, assets, and capabilities necessary for successful franchise growth, the Company operates a diversified platform of eight brands spanning modalities including Pilates, indoor cycling, barre, stretching, boxing, strength training, metabolic health, and yoga. In partnership with its franchisees and master franchisees, Xponential offers energetic, accessible, and personalized workout experiences led by highly qualified instructors in studio locations throughout the U.S. and internationally, with franchise, master franchise and international expansion agreements in 49 U.S. states, Puerto Rico, and 30 additional countries. Xponential's portfolio of brands includes Club Pilates, the largest Pilates brand in the United States; CycleBar, the largest indoor cycling brand by number of locations in the United States; StretchLab, a concept offering one-on-one and group stretching services; YogaSix, the largest franchised yoga brand in the United States; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements, and the largest Barre brand in the United States; Rumble, a boxing-inspired full body workout; BFT, a functional training and strength-based program; and Lindora, a provider of medically guided wellness and metabolic health solutions. For more information, please visit the Company's website at
